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Abstract: Precise quantification of antimicrobial treatment incidence (TI) is crucial for benchmarking.
Two widespread methods for treatment incidence quantification were compared for agreement. Field
data were obtained from 38 veal farms from 2016 to 2018 (1905 calves, 1864 treatments). Calculation
of TIswiss for calves was based on detailed treatment records using pharmacokinetic values from
the Swiss Veterinary Medicines Compendium. The method published by the European Medicines
Agency was used to calculate TI in defined daily doses (TIDDD). For each calf and treatment, TIswiss
and TIDDD were calculated on level of the antimicrobial class, drug, application route, and farm. The
quotient (Q) of TIswiss and TIDDD was calculated. Divergence in results between the two methods of
≤25% was arbitrarily set as good agreement. The agreement between TIswiss and TIDDD was mostly
good. On class level, good agreement was observed for treatments representing 71.5% of the TIDDD,
and 74.5% of the total TIDDD on drug level. Poor agreement was mainly observed for tylosin and
sulfadimidine. The agreement was better for parenteral than for oral treatments (81.6% vs. 72.3%).
For practically orientated calculation on farm level, good agreement was observed (77.5% of the
TIDDD). The TIDDD method showed mostly good agreement, especially for parenteral treatments.
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1. Introduction
Antimicrobial resistance (AMR) is likely to become an obstacle for human develop-
ment, as antimicrobials may become ineffective for disease control and health care costs
may rise considerably [1]. There is a large basis of evidence showing that antimicrobial use
(AMU) is a major driver for the development of AMR in human and veterinary medicine
through selection of resistant strains, which emphasizes the need to reduce AMU [2].
Different methods are used to quantify and compare AMU among countries, with the
aim of developing strategies to monitor drug use and to identify excessive or inadequate
use. Sales figures of antimicrobial therapeutic products have been published regularly
for various countries for more than a decade [3–6]. However, an important limitation of
the interpretation of sales figures is that antimicrobials cannot always be attributed to
different animal species and production branches, and dose or duration of the treatments
are rarely known. Thus, sales figures interpretation is difficult. Moreover, the amount
of antimicrobials sold is not identical to the amount used, as, e.g., therapeutic products
may expire before administration or packages may break. There is agreement that more
detailed data than sales figures are needed to estimate AMU more precisely at the levels of
the species, production branch, or farm [7].
Numerous methods and differing approaches have been developed to estimate AMU.
However, comparison of the results of different methods often requires complicated con-
version calculations or may be impossible. For example, the method for calculating the
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